Posts

Cullinan’s Zipalertinib Gains First-Line Momentum Against J&J and AstraZeneca in EGFR Exon 20 NSCLC

Cullinan and Taiho Report Phase III Win for Zipalertinib–Chemotherapy Combo in First-Line EGFR Exon 20 Insertion–Mutant NSCLC